Vincent Sibaud

TL;DR: Dermatologic irAEs induced by PD-1 or PD-L1 blockade therapy rarely result in significant morbidity or permanent discontinuation of treatment, however, early recognition and appropriate management are crucial for restricting dose-limiting toxicities.

TL;DR: Oral mucosal toxicities observed with targeted therapies, oral mucositis is the most frequent with mammalian target of rapamycin (mTOR) inhibitors, followed by stomatitis associated to multikinase angiogenesis and HER inhibitors, geographic tongue, oral hyperkeratotic lesions, lichenoid reactions, and hyperpigmentation.

TL;DR: This analysis represents a systematic review of the dermatological conditions reported with the use of taxanes, complemented by experience at comprehensive cancer centres and describes the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

TL;DR: This review provides the first available structured data on oral toxicities induced by the new recently FDA- and EMA-approved monoclonal antibodies targeting PD-1, and discusses clinical management of these targeted therapy-related oral changes.

TL;DR: The aim of this epidemiological survey was to assess the prevalence of sensitive skin and collect data on sensitive skin in the US population.